ACADIA Pharmaceuticals

ACAD73

High Quality

$17.02arrow_drop_down3.12%-$0.55

High Quality

ACAD73

$17.02

arrow_drop_down3.12%-$0.55

High Quality

Performance History

Key Stats
Open	$17.68
Prev. Close	$17.59
EPS	0.78
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-

	LOW	HIGH
Day Range	17.36	18.45
52 Week Range	14.34	32.59

Ratios







EPS	0.78

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About ACADIA Pharmaceuticals (ACAD)

ACADIA Pharmaceuticals Inc. (ACAD) is a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders. The company's primary therapeutic focus is on Parkinson's disease psychosis (PDP), schizophrenia, and major depressive disorder (MDD). ACADIA's lead product, NUPLAZID® (pimavanserin), is the first and only FDA-approved treatment for hallucinations and delusions associated with PDP. NUPLAZID is also being evaluated for the treatment of dementia-related psychosis (DRP) and as an adjunctive treatment for MDD. ACADIA is committed to improving the lives of patients and their caregivers with this breakthrough therapy.

ACADIA Pharmaceuticals Inc. (ACAD) is listed on the NASDAQ stock exchange under the ticker symbol ACAD. As of October 29, 2021, the stock price for ACADIA Pharmaceuticals Inc. was $19.47 per share. Over the past year, the stock has traded in a range of $16.29 to $57.68. The market capitalization of ACADIA Pharmaceuticals Inc. is approximately $3.03 billion. ACADIA Pharmaceuticals Inc. is part of the healthcare sector and is classified under the biotechnology industry. The company's PEG ratio is currently not available. ACADIA Pharmaceuticals Inc. operates in the United States and has a global presence in several other countries.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Mr. Stephen R. Davis J.D.
Headquarters: San Diego
Employees: 540
Exchange: NASDAQ

Keep an eye on ACADIA Pharmaceuticals

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is ACADIA Pharmaceuticals 's (ACAD) price per share?

The current price per share for ACADIA Pharmaceuticals (ACAD) is $17.02. The stock has seen a price change of -$0.55 recently, indicating a -3.13% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for ACADIA Pharmaceuticals (ACAD)?

For ACADIA Pharmaceuticals (ACAD), the 52-week high is $32.59, which is 91.48% from the current price. The 52-week low is $14.35, the current price is 18.65% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is ACADIA Pharmaceuticals (ACAD) a growth stock?

ACADIA Pharmaceuticals (ACAD) has shown an average price growth of -3.55% over the past three years. It has received a score of 48 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying ACADIA Pharmaceuticals as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is ACADIA Pharmaceuticals (ACAD) stock price performance year to date (YTD)?

As of the latest data, ACADIA Pharmaceuticals (ACAD) has a year-to-date price change of -44.85%. Over the past month, the stock has experienced a price change of 13.54%. Over the last three months, the change has been 12.42%. Over the past six months, the figure is 14.54%. Looking at a longer horizon, the five-year price change stands at -62.57%.

help

Is ACADIA Pharmaceuticals (ACAD) a profitable company?

ACADIA Pharmaceuticals (ACAD) has a net income of -$61.29M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 93.7% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 12.64% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $726.44M, with a revenue growth rate of 40.45%, providing insight into the company's sales performance and growth. The gross profit is $680.71M. Operating income is noted at -$73.38M. Furthermore, the EBITDA is $124.54M.

help

What is the market capitalization of ACADIA Pharmaceuticals (ACAD)?

ACADIA Pharmaceuticals (ACAD) has a market capitalization of $2.83B. The average daily trading volume is 17.15, indicating the stock's liquidity and investor engagement.